Conclusions

This interim analysis shows an obvious tread toward benefits from ENI, and the addition of erlotinib to ENI combined with concurrent chemotherapy further prolongs OS in patients with oesophageal SCC. However, the results with respect to the value of ENI or erlotinib alone were not decisive; final OS analysis is estimated for late 2015.